Systemic sclerosis & Raynaud's
Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study
Authors' conclusion
RTX demonstrated comparable safety and efficacy as CY in patients with SSc-ILD.
Study context
- Population
- Patients with SSc-ILD
- Participants
- 20 vs 30
- Exposure
- Rituximab (RTX) vs intravenous cyclophosphamide (CY)
- RTXn = 20
- CYn = 30reference
- Outcome
- Absolute changes in forced vital capacity (FVC) and serum KL-6 levels from baseline
- Follow-up
- 6 and 12 months after treatment
Methodological detailsstabilised inverse probability of treatment weighting based on propensity scores
- Stabilised inverse probability of treatment weighting based on propensity scores
Main finding
As reported in the abstract
Median FVC increase from baseline · 6 and 12 months
RTX
50 and 60
median · ml
CY
40 and 15
median · ml
Observational data: associations, not effects.
Further findings
Changes in serum KL-6 levels
- Identical in both groups after adjustment
Incidence of progression (progressive pulmonary fibrosis definition)
- Identical in both groups after adjustment
Original publication
Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study. Arthritis Res Ther. Published 17 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →